Teva Pharmaceuticals Scholars awardees describe discoveries on cancer, hepatitis, drug delivery
Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.
PHILADELPHIA, Aug. 21, 2012 — Current recipients of a prestigious award from the world’s largest scientific society will present results of their research here today, and new recipients of the Teva Pharmaceuticals Scholars Grants will be announced during a symposium at the 244th National Meeting & Exposition of the American Chemical Society (ACS).
The presentations, from 1 p.m. to 5 p.m. in Room 203AB of the Pennsylvania Convention Center, feature new discoveries on anti-cancer drugs made from antibiotics, a potential new drug for hepatitis C and a new approach for delivering drugs to the body. ACS’ Board Standing Committee on Grants and Awards and the ACS Division of Organic Chemistry are co-sponsoring the symposium, which will include an intermission reception hosted by Teva Pharmaceuticals, which funds the scholars grants.
The Teva Pharmaceuticals Scholars Grants are $100,000, three-year awards given to researchers in the area of organic chemistry, with “potential or direct connections with medicinal chemistry, such that the successful results would be of practical benefit to the discovery of organic compounds useful as human medicines.”
Presentations at this symposium will include:
- Brian Stoltz, Ph.D., of the California Institute of Technology, “A novel approach to antitumor antibiotics: Using the power of benzyne in synthesis.”
- Alexander Dieters, Ph.D., of North Carolina State University, “Discovery and application of small molecule modifiers of microRNA function.”
- Xin Guo, Ph.D., of the University of the Pacific, “Trans-2-aminocyclohexanol-based lipids as pH-sensitive conformational switches in liposomes for drug delivery.”
A new group of Teva Pharmaceuticals Scholars will be announced during the event.
To automatically receive news releases from the American Chemical Society contact email@example.com.